KR20170042598A - 항체와 조합된 면역조절 화합물을 이용하여 다발성 골수종을 치료하는 방법 - Google Patents

항체와 조합된 면역조절 화합물을 이용하여 다발성 골수종을 치료하는 방법 Download PDF

Info

Publication number
KR20170042598A
KR20170042598A KR1020177004321A KR20177004321A KR20170042598A KR 20170042598 A KR20170042598 A KR 20170042598A KR 1020177004321 A KR1020177004321 A KR 1020177004321A KR 20177004321 A KR20177004321 A KR 20177004321A KR 20170042598 A KR20170042598 A KR 20170042598A
Authority
KR
South Korea
Prior art keywords
compound
alkyl
another embodiment
administered
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020177004321A
Other languages
English (en)
Korean (ko)
Inventor
안잔 타쿠타
모하메드 후세인
크리스티앙 자크
Original Assignee
셀진 코포레이션
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54035318&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR20170042598(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 셀진 코포레이션 filed Critical 셀진 코포레이션
Publication of KR20170042598A publication Critical patent/KR20170042598A/ko
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
KR1020177004321A 2014-08-22 2015-08-20 항체와 조합된 면역조절 화합물을 이용하여 다발성 골수종을 치료하는 방법 Withdrawn KR20170042598A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462040918P 2014-08-22 2014-08-22
US62/040,918 2014-08-22
PCT/US2015/046091 WO2016029004A1 (en) 2014-08-22 2015-08-20 Methods of treating multiple myeloma with immunomodulatory compounds in combination with antibodies

Publications (1)

Publication Number Publication Date
KR20170042598A true KR20170042598A (ko) 2017-04-19

Family

ID=54035318

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020177004321A Withdrawn KR20170042598A (ko) 2014-08-22 2015-08-20 항체와 조합된 면역조절 화합물을 이용하여 다발성 골수종을 치료하는 방법

Country Status (24)

Country Link
US (1) US10034872B2 (OSRAM)
EP (2) EP3925609B1 (OSRAM)
JP (2) JP7120763B2 (OSRAM)
KR (1) KR20170042598A (OSRAM)
CN (1) CN107073115A (OSRAM)
AU (2) AU2015305449B2 (OSRAM)
BR (1) BR112017003620A2 (OSRAM)
CA (1) CA2958867A1 (OSRAM)
CL (1) CL2017000416A1 (OSRAM)
DK (1) DK3182996T3 (OSRAM)
EA (1) EA201790439A1 (OSRAM)
ES (2) ES2940302T3 (OSRAM)
FI (1) FI3182996T3 (OSRAM)
HR (1) HRP20230265T1 (OSRAM)
HU (1) HUE061382T2 (OSRAM)
IL (1) IL250724A0 (OSRAM)
LT (1) LT3182996T (OSRAM)
MX (1) MX388383B (OSRAM)
PL (1) PL3182996T3 (OSRAM)
PT (1) PT3182996T (OSRAM)
RS (1) RS64038B1 (OSRAM)
SI (1) SI3182996T1 (OSRAM)
SM (1) SMT202300081T1 (OSRAM)
WO (1) WO2016029004A1 (OSRAM)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023014082A1 (ko) * 2021-08-04 2023-02-09 주식회사 아이비스바이오 물질 특성이 개선된 면역조절아마이드 유도체
WO2023090888A1 (ko) * 2021-11-19 2023-05-25 케이블루바이오 주식회사 신규한 사환구조 트리테르펜 화합물을 유효성분으로 포함하는 다발성골수종의 예방 또는 치료용 조성물

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017003990A1 (en) 2015-06-29 2017-01-05 Bristol-Myers Squibb Company Immunotherapeutic dosing regimens comprising pomalidomide and an anti-cs1 antibody for treating cancer
RU2771166C2 (ru) * 2016-12-21 2022-04-27 Биотерикс, Инк. Производные тиенопиррола для применения для нацеливания на белки, композиции с указанными производными, способы и применения
TW201922282A (zh) * 2017-10-13 2019-06-16 大陸商江蘇恆瑞醫藥股份有限公司 Ｐｄ-１抗體和表觀遺傳調節劑聯合在製備治療腫瘤的藥物中的用途
PL3703750T3 (pl) 2017-11-01 2025-04-07 Juno Therapeutics, Inc. Chimeryczne receptory antygenowe specyficzne dla antygenu dojrzewania komórek b i kodujące polinukleotydy
AU2019284605A1 (en) * 2018-06-13 2020-12-10 Biotheryx, Inc. Fused thiophene compounds
KR20210069642A (ko) * 2018-10-01 2021-06-11 셀진 코포레이션 암 치료를 위한 병용 요법
AU2019377854A1 (en) 2018-11-08 2021-05-27 Juno Therapeutics, Inc. Methods and combinations for treatment and T cell modulation
WO2020102226A1 (en) * 2018-11-13 2020-05-22 Nantcell, Inc Combination therapies for multiple myeloma
CN111606883B (zh) * 2019-02-25 2023-05-09 上海科技大学 基于戊二酰亚胺骨架的含硫化合物及其应用
US20230028293A1 (en) * 2019-12-08 2023-01-26 The Regents Of The University Of Colorado, A Body Corporate Multiple myeloma combination therapies based on protein translation inhibitors and immunomodulators
US20230042129A1 (en) * 2019-12-11 2023-02-09 Erasmus University Medical Center Rotterdam Method for Monitoring of Deep Remissions in Multiple Myeloma and Other Plasma Cell Dyscrasias
WO2022072538A1 (en) * 2020-09-30 2022-04-07 Biotheryx, Inc. Antibody-drug conjugates, pharmaceutical compositions thereof, and their therapeutic applications
MX2023008296A (es) 2021-01-13 2023-09-29 Monte Rosa Therapeutics Inc Compuestos de isoindolinona.

Family Cites Families (133)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1164829B (de) 1961-04-26 1964-03-05 Bayer Ag Verfahren zur elektrophotographischen Herstellung von Bildern mit Fluessigkeitsaerosolen
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
US4994443A (en) 1982-12-20 1991-02-19 The Children's Medical Center Corporation Inhibition of angiogenesis
US5001116A (en) 1982-12-20 1991-03-19 The Children's Medical Center Corporation Inhibition of angiogenesis
US4551177A (en) 1984-04-23 1985-11-05 National Starch And Chemical Corporation Compressible starches as binders for tablets or capsules
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US5391485A (en) 1985-08-06 1995-02-21 Immunex Corporation DNAs encoding analog GM-CSF molecules displaying resistance to proteases which cleave at adjacent dibasic residues
US4810643A (en) 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor
JPS63500636A (ja) 1985-08-23 1988-03-10 麒麟麦酒株式会社 多分化能性顆粒球コロニー刺激因子をコードするｄｎａ
US5974203A (en) 1988-04-11 1999-10-26 Canon Kabushiki Kaisha Pattern recognition communication apparatus for transmitting and receiving image data
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
JPH05503302A (ja) 1990-10-12 1993-06-03 アムジエン・インコーポレーテツド 巨核球成熟因子
US5387421A (en) 1991-01-31 1995-02-07 Tsrl, Inc. Multi stage drug delivery system
AU1531492A (en) 1991-02-14 1992-09-15 Rockefeller University, The Method for controlling abnormal concentration tnf alpha in human tissues
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5358941A (en) 1992-12-02 1994-10-25 Merck & Co., Inc. Dry mix formulation for bisphosphonic acids with lactose
US5360352A (en) 1992-12-24 1994-11-01 The Whitaker Corporation Wire retainer for current mode coupler
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
US6114355A (en) 1993-03-01 2000-09-05 D'amato; Robert Methods and compositions for inhibition of angiogenesis
US6228879B1 (en) 1997-10-16 2001-05-08 The Children's Medical Center Methods and compositions for inhibition of angiogenesis
US20010056114A1 (en) 2000-11-01 2001-12-27 D'amato Robert Methods for the inhibition of angiogenesis with 3-amino thalidomide
US5629327A (en) 1993-03-01 1997-05-13 Childrens Hospital Medical Center Corp. Methods and compositions for inhibition of angiogenesis
US5594637A (en) 1993-05-26 1997-01-14 Base Ten Systems, Inc. System and method for assessing medical risk
US5698579A (en) 1993-07-02 1997-12-16 Celgene Corporation Cyclic amides
US5641758A (en) 1993-11-10 1997-06-24 Kluge; Michael Cytarabine derivatives, the preparation and use thereof
US6432924B1 (en) 1993-12-26 2002-08-13 East Carolina University Method of treating disorders characterized by overexpression of cytidine deaminase or deoxycytidine deaminase
GB9412394D0 (en) 1994-06-21 1994-08-10 Danbiosyst Uk Colonic drug delivery composition
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
WO1996013790A1 (en) 1994-10-28 1996-05-09 Advanced Health Med-E-Systems Corporation Prescription management system
US5593696A (en) 1994-11-21 1997-01-14 Mcneil-Ppc, Inc. Stabilized composition of famotidine and sucralfate for treatment of gastrointestinal disorders
US5619991A (en) 1995-04-26 1997-04-15 Lucent Technologies Inc. Delivery of medical services using electronic data communications
US5731325A (en) 1995-06-06 1998-03-24 Andrulis Pharmaceuticals Corp. Treatment of melanomas with thalidomide alone or in combination with other anti-melanoma agents
US5643915A (en) 1995-06-06 1997-07-01 Andrulis Pharmaceuticals Corp. Treatment of ischemia/reperfusion injury with thalidomide alone or in combination with other therapies
US5832449A (en) 1995-11-13 1998-11-03 Cunningham; David W. Method and system for dispensing, tracking and managing pharmaceutical trial products
US6063026A (en) 1995-12-07 2000-05-16 Carbon Based Corporation Medical diagnostic analysis system
HU228769B1 (en) 1996-07-24 2013-05-28 Celgene Corp Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1-oxoisoindolines and their use for production of pharmaceutical compositions for mammals to reduce the level of tnf-alpha
US5798368A (en) 1996-08-22 1998-08-25 Celgene Corporation Tetrasubstituted 2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolines and method of reducing TNFα levels
ATE530542T1 (de) 1996-07-24 2011-11-15 Celgene Corp Amino substituierte 2-(2,6-dioxopiperidin-3-yl)- phthalimide zur verringerung der tnf-alpha-stufen
US5635517B1 (en) 1996-07-24 1999-06-29 Celgene Corp Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines
US6281230B1 (en) 1996-07-24 2001-08-28 Celgene Corporation Isoindolines, method of use, and pharmaceutical compositions
CA2262906C (en) 1996-08-12 2006-10-31 Celgene Corporation Novel immunotherapeutic agents and their use in the reduction of cytokine levels
US5924074A (en) 1996-09-27 1999-07-13 Azron Incorporated Electronic medical records system
DK1920773T3 (da) 1996-11-05 2011-03-28 Childrens Medical Center Thalidomid og dexamethason til behandling af tumorer
US6131090A (en) 1997-03-04 2000-10-10 Pitney Bowes Inc. Method and system for providing controlled access to information stored on a portable recording medium
ATE302597T1 (de) 1997-06-06 2005-09-15 Depomed Inc Im magen verweilende orale dosierungsformen von wasserlöslichen arzneistoffen mit kontrollierter freisetzung
US6635280B2 (en) 1997-06-06 2003-10-21 Depomed, Inc. Extending the duration of drug release within the stomach during the fed mode
AU8909898A (en) 1997-08-22 1999-03-16 Deka Products Limited Partnership Health care system and method for physician order entry
US5955476A (en) 1997-11-18 1999-09-21 Celgene Corporation Substituted 2-(2,6-dioxo-3-fluoropiperidin-3-yl)-isoindolines and method of reducing inflammatory cytokine levels
US5874448A (en) 1997-11-18 1999-02-23 Celgene Corporation Substituted 2-(2,6 dioxo-3-fluoropiperidin-3-yl)-isoindolines and method of reducing TNFα levels
US6096757A (en) 1998-12-21 2000-08-01 Schering Corporation Method for treating proliferative diseases
BR9908811A (pt) 1998-03-16 2000-12-05 Celgene Corp Composto, composição farmacêutica e seu uso no tratamento de mamìferos
JPH11286455A (ja) 1998-03-31 1999-10-19 Kanebo Ltd 骨髄異形成症候群治療薬
US6673828B1 (en) 1998-05-11 2004-01-06 Children's Medical Center Corporation Analogs of 2-Phthalimidinoglutaric acid
US6045501A (en) 1998-08-28 2000-04-04 Celgene Corporation Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug
US6020358A (en) 1998-10-30 2000-02-01 Celgene Corporation Substituted phenethylsulfones and method of reducing TNFα levels
US20030013739A1 (en) 1998-12-23 2003-01-16 Pharmacia Corporation Methods of using a combination of cyclooxygenase-2 selective inhibitors and thalidomide for the treatment of neoplasia
GB9904585D0 (en) 1999-02-26 1999-04-21 Gemini Research Limited Clinical and diagnostic database
ATE306469T1 (de) 1999-03-18 2005-10-15 Celgene Corp Substituierte 1-oxo- und 1,3-dioxoisoindoline und ihre verwendung in pharmazeutischen zusammensetzungen zur senkung des spiegels inflammatorisch wirkender cytokine
US20010021380A1 (en) 1999-04-19 2001-09-13 Pluenneke John D. Soluble tumor necrosis factor receptor treatment of medical disorders
US7629360B2 (en) 1999-05-07 2009-12-08 Celgene Corporation Methods for the treatment of cachexia and graft v. host disease
AU6015400A (en) 1999-07-16 2001-02-05 Amato Pharmaceutical Products, Ltd. Glycyrrhizin preparations for transmucosal absorption
US6202923B1 (en) 1999-08-23 2001-03-20 Innovation Associates, Inc. Automated pharmacy
US6878733B1 (en) 1999-11-24 2005-04-12 Sugen, Inc. Formulations for pharmaceutical agents ionizable as free acids or free bases
US7182953B2 (en) 1999-12-15 2007-02-27 Celgene Corporation Methods and compositions for the prevention and treatment of atherosclerosis restenosis and related disorders
US6326388B1 (en) 1999-12-21 2001-12-04 Celgene Corporation Substituted 1,3,4-oxadiazoles and a method of reducing TNF-alpha level
CA2319872C (en) 2000-02-02 2012-06-19 Chun-Ying Huang Pharmaceutical composition for the treatment of hepatocellular carcinoma
MXPA02007254A (es) 2000-02-04 2002-12-09 Depomed Inc Forma de dosis de cubierta-y-nucleo que se aproxima a liberacion de droga de orden cero.
SI21172A (sl) 2000-03-17 2003-10-31 Cell Therapeutics, Inc. Konjugati poliglutaminska kislina-kamptotecin in postopki za pripravo
AU2001249755A1 (en) 2000-03-31 2001-10-15 Celgene Corporation Inhibition of cyclooxygenase-2 activity
NZ522767A (en) 2000-05-15 2004-07-30 Celgene Corp Thalidomide and a topoisomerase inhibitor for the treatment of cancer
DE60118547T2 (de) 2000-05-15 2007-02-01 Celgene Corp. Pharmazeutische zusammensetzung zur behandlung von kolorektalem krebs welche thalidomid und irinotecan enthält
WO2002015926A1 (en) 2000-08-24 2002-02-28 Kirin Beer Kabushiki Kaisha c-mpl LIGAND-CONTAINING MEDICINAL COMPOSITIONS FOR INCREASING PLATELETS AND ERYTHROCYTES
US6315720B1 (en) 2000-10-23 2001-11-13 Celgene Corporation Methods for delivering a drug to a patient while avoiding the occurrence of an adverse side effect known or suspected of being caused by the drug
US6458810B1 (en) 2000-11-14 2002-10-01 George Muller Pharmaceutically active isoindoline derivatives
US7812169B2 (en) 2000-11-30 2010-10-12 The Children's Medical Center Corporation Method of synthesis of 4-amino-thalidomide enantiomers
US20020128228A1 (en) 2000-12-01 2002-09-12 Wen-Jen Hwu Compositions and methods for the treatment of cancer
US7091353B2 (en) 2000-12-27 2006-08-15 Celgene Corporation Isoindole-imide compounds, compositions, and uses thereof
US20030045552A1 (en) 2000-12-27 2003-03-06 Robarge Michael J. Isoindole-imide compounds, compositions, and uses thereof
GB0102342D0 (en) 2001-01-30 2001-03-14 Smithkline Beecham Plc Pharmaceutical formulation
ATE450529T1 (de) 2001-02-27 2009-12-15 Governement Of The United Stat Analoga von thalidomid als angiogeneseinhibitoren
ES2325916T3 (es) 2001-08-06 2009-09-24 The Children's Medical Center Corporation Actividad antiangiogenica de analogos de talidomida sustituidos con nitrogeno.
US6723340B2 (en) 2001-10-25 2004-04-20 Depomed, Inc. Optimal polymer mixtures for gastric retentive tablets
JP4027693B2 (ja) 2002-03-20 2007-12-26 トリニティ工業株式会社 塗料送給装置及びバルブユニット
US20030220254A1 (en) 2002-03-29 2003-11-27 Texas Tech University System Composition and method for preparation of an oral dual controlled release formulation of a protein and inhibitor
CA2481387A1 (en) 2002-04-12 2003-10-23 Celgene Corporation Methods for identification of modulators of angiogenesis, compounds discovered thereby, and methods of treatment using the compounds
US7498171B2 (en) 2002-04-12 2009-03-03 Anthrogenesis Corporation Modulation of stem and progenitor cell differentiation, assays, and uses thereof
US7323479B2 (en) 2002-05-17 2008-01-29 Celgene Corporation Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline
US7393862B2 (en) 2002-05-17 2008-07-01 Celgene Corporation Method using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of certain leukemias
CN1668296A (zh) 2002-05-17 2005-09-14 细胞基因公司 使用选择性细胞因子抑制性药物用于治疗和控制癌症和其它疾病的方法及组合物
US7968569B2 (en) 2002-05-17 2011-06-28 Celgene Corporation Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione
EP2915533B1 (en) 2002-05-17 2017-09-13 Celgene Corporation Pharmaceutical compositions for treating cancer
US8404716B2 (en) 2002-10-15 2013-03-26 Celgene Corporation Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
US7189740B2 (en) 2002-10-15 2007-03-13 Celgene Corporation Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes
US8404717B2 (en) 2002-10-15 2013-03-26 Celgene Corporation Methods of treating myelodysplastic syndromes using lenalidomide
US20040091455A1 (en) 2002-10-31 2004-05-13 Zeldis Jerome B. Methods of using and compositions comprising immunomodulatory compounds for treatment and management of macular degeneration
AU2003286836A1 (en) 2002-10-31 2004-06-07 Supergen, Inc. Pharmaceutical formulations targeting specific regions of the gastrointestinal tract
US20040152632A1 (en) 2002-11-06 2004-08-05 Wyeth Combination therapy for the treatment of acute leukemia and myelodysplastic syndrome
US7563810B2 (en) 2002-11-06 2009-07-21 Celgene Corporation Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases
US6943249B2 (en) 2003-03-17 2005-09-13 Ash Stevens, Inc. Methods for isolating crystalline Form I of 5-azacytidine
US6887855B2 (en) 2003-03-17 2005-05-03 Pharmion Corporation Forms of 5-azacytidine
CL2004001004A1 (es) 2003-05-19 2005-03-18 Upjohn Co Combinacion farmaceutica que comprende irinotecan y revimid para tratar el mieloma multiple.
UA83504C2 (en) 2003-09-04 2008-07-25 Селджин Корпорейшн Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione
MXPA06011798A (es) 2004-04-14 2007-01-16 Celgene Corp Metodos de uso y composiciones que comprenden compuestos inmunomoduladores para el tratamiento y manejo de sindromes mielodisplasticos.
EP1744748A4 (en) 2004-04-14 2009-08-12 Celgene Corp METHOD FOR USE OF SELECTIVE CYTOKINE-INHIBITORY MEDICAMENTS AND COMPOSITIONS CONTAINING THEREOF FOR THE TREATMENT AND SUPPLY OF MYELODYSPLASTIC SYNDROMES
US20060128654A1 (en) 2004-12-10 2006-06-15 Chunlin Tang Pharmaceutical formulation of cytidine analogs and derivatives
US20070155791A1 (en) 2005-12-29 2007-07-05 Zeldis Jerome B Methods for treating cutaneous lupus using aminoisoindoline compounds
US8058260B2 (en) 2006-05-22 2011-11-15 Xenoport, Inc. 2′-C-methyl-ribofuranosyl cytidine prodrugs, pharmaceutical compositions and uses thereof
PL2068874T3 (pl) 2006-08-07 2015-06-30 Abbvie Biotherapeutics Inc Sposoby leczenia szpiczaka mnogiego z użyciem terapii skojarzonych opartych na przeciwciałach anty-cs1
WO2008027049A1 (en) 2006-08-30 2008-03-06 Temple University - Of The Commonwealth System Of Higher Education Composition and methods for the treatment of myelodysplastic syndrome and acute myeloid leukemia
US8877780B2 (en) 2006-08-30 2014-11-04 Celgene Corporation 5-substituted isoindoline compounds
US20080057086A1 (en) 2006-09-01 2008-03-06 Pharmion Corporation Colon-targeted oral formulations of cytidine analogs
RS52349B (sr) 2006-09-26 2012-12-31 Celgene Corporation 5-supstituisani derivati hinazolinona kao antitumorski agensi
NZ584425A (en) 2007-09-26 2012-03-30 Celgene Corp 6-, 7-, or 8-substituted quinazolinone derivatives and compositions comprising and methods of using the same
JO2778B1 (en) 2007-10-16 2014-03-15 ايساي انك Certain Compounds, Compositions and Methods
CA2742252A1 (en) 2007-11-01 2009-05-07 Celgene Corporation Cytidine analogs for treatment of myelodysplastic syndromes
EP2695609B1 (en) 2008-05-15 2019-12-11 Celgene Corporation Oral formulations of cytidine analogs and methods of use thereof
NZ592425A (en) 2008-10-29 2013-04-26 Celgene Corp Isoindoline compounds for use in the treatment of cancer
US8628927B2 (en) 2008-11-07 2014-01-14 Sequenta, Inc. Monitoring health and disease status using clonotype profiles
EP2391355B1 (en) 2009-05-19 2017-01-18 Celgene Corporation Formulations of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione
LT3202460T (lt) 2010-02-11 2019-10-10 Celgene Corporation Arilmetoksi izoindolino dariniai ir kompozicijos, apimantys ir jų panaudojimo būdus
RU2017120977A (ru) 2011-03-11 2018-11-15 Селджин Корпорейшн Способ лечения рака с использованием 3-(5-амино-2-метил-4-оксо-4h-хиназолин-3-ил)пиперидин-2,6-диона
US20140142128A1 (en) 2012-11-20 2014-05-22 Celgene Avilomics Research, Inc. Methods of treating a disease or disorder associated with bruton's tyrosine kinase
HK1245140A1 (zh) * 2014-12-31 2018-08-24 Celgene Corporation 使用自然杀伤细胞治疗血液病症、实体瘤或感染性疾病的方法
US9713375B1 (en) 2015-02-26 2017-07-25 Brett Einar Rahm Collapsible portable table
WO2017003990A1 (en) * 2015-06-29 2017-01-05 Bristol-Myers Squibb Company Immunotherapeutic dosing regimens comprising pomalidomide and an anti-cs1 antibody for treating cancer

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023014082A1 (ko) * 2021-08-04 2023-02-09 주식회사 아이비스바이오 물질 특성이 개선된 면역조절아마이드 유도체
WO2023090888A1 (ko) * 2021-11-19 2023-05-25 케이블루바이오 주식회사 신규한 사환구조 트리테르펜 화합물을 유효성분으로 포함하는 다발성골수종의 예방 또는 치료용 조성물

Also Published As

Publication number Publication date
DK3182996T3 (da) 2023-03-13
SI3182996T1 (sl) 2023-04-28
HRP20230265T1 (hr) 2023-04-14
EP3925609B1 (en) 2025-07-30
MX388383B (es) 2025-03-19
LT3182996T (lt) 2023-03-10
RS64038B1 (sr) 2023-04-28
EP3925609A1 (en) 2021-12-22
EP3182996B1 (en) 2022-12-28
EA201790439A1 (ru) 2017-07-31
MX2017002382A (es) 2017-05-17
IL250724A0 (en) 2017-04-30
ES2940302T3 (es) 2023-05-05
US20160051530A1 (en) 2016-02-25
CN107073115A (zh) 2017-08-18
CL2017000416A1 (es) 2017-09-08
FI3182996T3 (fi) 2023-03-28
JP2021006557A (ja) 2021-01-21
JP2017525713A (ja) 2017-09-07
EP3182996A1 (en) 2017-06-28
PT3182996T (pt) 2023-03-21
AU2015305449A1 (en) 2017-03-16
AU2015305449B2 (en) 2021-05-06
SMT202300081T1 (it) 2023-05-12
CA2958867A1 (en) 2016-02-25
HUE061382T2 (hu) 2023-06-28
US10034872B2 (en) 2018-07-31
WO2016029004A1 (en) 2016-02-25
JP7120763B2 (ja) 2022-08-17
ES3043078T3 (en) 2025-11-24
BR112017003620A2 (pt) 2017-12-05
PL3182996T3 (pl) 2023-04-17
AU2021209158A1 (en) 2021-08-19

Similar Documents

Publication Publication Date Title
KR20170042598A (ko) 항체와 조합된 면역조절 화합물을 이용하여 다발성 골수종을 치료하는 방법
RU2406501C2 (ru) Способы применения 3-(4-амино-1-оксо-1, 3-дигидроизоиндол-2-ил)пиперидин-2, 6-диона для лечения определенных типов лейкоза
JP5839770B2 (ja) 癌および他の疾患を治療および管理するための免疫調節性化合物を用いた方法および組成物
JP4754967B2 (ja) １−オキソ−２−（２，６−ジオキソピペリジン−３−イル）−４−メチルイソインドリンを含む脳腫瘍の治療及び管理のための医薬組成物
RU2348407C2 (ru) Способы и композиции с использованием иммуномодулирующих соединений для лечения и поддержания состояния при раке и других заболеваниях
JP4481828B2 (ja) 骨髄異形成症候群を治療および管理するための免疫調節化合物の使用方法およびそれを含む組成物
KR20150039850A (ko) 3-(4-((4-모르포리노메틸)벤질)옥시)-1-옥소이소인돌린-2-일)피페리딘-2,6-디온을 이용한 암의 치료방법
JP2013526525A (ja) レナリドミド及びアザシチジン併用療法による骨髄異形成症候群の治療方法
JP2010013482A (ja) 癌および他の疾患を治療および管理するための選択的サイトカイン阻害薬を用いた方法および組成物
US20080199422A1 (en) Method for the Treatment of Myelodysplastic Syndromes Using 1-Oxo-2-(2,6-Dioxopiperidin-3-Yl-)-4-Methylisoindoline
AU2014202561B2 (en) Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of myelodysplastic syndromes
HK1125856A (en) Methods using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of certain leukemias

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20170216

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1202 Submission of document of withdrawal before decision of registration

Comment text: [Withdrawal of Procedure relating to Patent, etc.] Withdrawal (Abandonment)

Patent event code: PC12021R01D

Patent event date: 20170913

WITB Written withdrawal of application